|
|
|
|
|
Darbepoetin_alfa: profile and news
DG News ALTANTA, GA -- December 16, 2005 -- A meta-analysis of randomized placebo-controlled trials indicates that darbepoetin alfa treatment is associated with ... Darbepoetin Alfa (Aranesp) Data Suggests Major Response in Anemic ... Dec 16, 2005 DG News ...[Presentation title: A Phase 2, Single-Arm, Open-Label Trial To Evaluate the Effectiveness of Darbepoetin alfa for the Treatment of Anemia in Patients with Low ... Coordinated Dosing of Anti-Anemia, Anti-Cancer Therapies Works ... Dec 15, 2005 DG News 15, 2005 -- Patients undergoing treatment for cancer could be prevented from developing anemia and its complications by administering darbepoetin alfa on the ... New Medicare Claims Monitoring System for Epoetin, Darbepoetin Use Dec 9, 2005 Medscape (subscription) A new Centers for Medicare & Medicaid Services (CMS) policy for monitoring and coverage of erythropoietin (EPO; Epogen) or darbepoetin alfa (Aranesp) for ... Roche Announces Successful Completion of Four Pivotal Phase III ... Dec 16, 2005 PR Newswire (press release), The third study was designed to evaluate IV CERA in the maintenance of Hb levels in CKD patients on dialysis previously maintained on IV darbepoetin alfa. ... Updated Interim Aranesp(R) Phase 2 Data Suggest Major Response in ... Dec 11, 2005 Business Wire (press release), ...company, today announced updated interim data from a Phase 2 study evaluating the use of 500 mcg of Aranesp(R) (darbepoetin alfa) administered every three ... Benefits Of Aranesp Dosed Every Three Weeks For Chemotherapy ... Dec 12, 2005 Medical News Today (press release), ...interim results from the first multi-center, randomized, double-blind, placebo-controlled, Phase 3 trial of Aranesp® (darbepoetin alfa) administered every ... Interim aranesp data suggest major response in anemic patients ... Dec 12, 2005 EurekAlert (press release), ...biotechnology company, today announced updated interim data from a Phase 2 study evaluating the use of 500 mcg of Aranesp darbepoetin alfa) administered every ... Aranesp® Effective in Low and Intermediate Risk Myelodysplastic ... Dec 7, 2005 Cancer Consultants (press release), Researchers from Italy have demonstrated that long-acting Aranesp (darbepoetin alfa) is as effective as Procrit® (epoetin alfa) for the treatment of patients ... Investigative Drug Aranesp (Darbepoetin) Effective for ... Dec 14, 2005 DG News ...[Presentation title: Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin alfa Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia. ... Drug increases hemoglobin in Myelodysplastic Syndrome Dec 13, 2005 MedIndia, Patients with Bone marrow disorder Myelodysplastic Syndrome (MDS), treated with 500 mcg of Aranesp (Darbepoetin alfa) for every three weeks found to improve ... Drug cuts transfusions in half for chemo patients Dec 15, 2005 Cancerfacts.com, It is the first large, multi-center, comparison trial of Aranesp® (darbepoetin alfa) administered every three weeks in cancer patients with anemia resulting ... Aranesp: pure red cell aplasia and severe anemia associated with ... Dec 4, 2005 Xagena.it, Amgen has informed Health Care Professionals that sections of the product prescribing information for Aranesp ( Darbepoetin alfa ) have been updated regarding ... Other information Indication For treatment of anemia (from renal transplants or certain HIV treatment) Pharmacology Used in the treatment of anemia. Involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass. Mechanism Of Action Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation. Drug Category Antianemic Agents; hematopoietic agents (20:16.00) Brand Names/Synonyms Erythropoietin precursor;Epoetin; Aranesp (Amgen Inc.) Dosage Forms SOLUTION Absorption Not Available Interactions Not Available Chemical IUPAC Name Human erythropoietin Chemical Formula C815H1317N233O241S5 Half Life Not Available Drug Type Approved Drug # Accession No BIOD00032 CAS Registry Number 11096-26-7 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |